4 ms·
https://www.prnewswire.com/news-releases/japans-ministry-of-health-labour-and-welfare-approves-csl-and-arcturus-therapeutics-arct-154-the-first-self-amplifying-
by hammock 2y ago
https://www.prnewswire.com/news-releases/japans-ministry-of-health-labour-and-welfare-approves-csl-and-arcturus-therapeutics-arct-154-the-first-self-amplifying-mrna-vaccine-approved-for-covid-in-adults-301999193.html https://www.prnewswire.com/news-releases/japans-ministry-of-...
Your characterization is inaccurate, of both the reporting and the technology
- gus_massa 2y agoThanks. Very interesting. From the research paper: > The ARCT-154 study vaccine consists of sa-mRNA encapsulated in lipid nanoparticles. The RNA comprises a replicon based upon Venezuela equine encephalitis virus (VEEV) in which RNA coding for the VEEV structural proteins has been replaced with RNA coding for the full-length spike (S) glycoprotein of the SARS-CoV-2 D614G variant. IIUC the RNA makes copies of itself inside the cell, but it does not get a capsule of proteins to travel and invade other cells. Is this correct? (A few more details in https://en.wikipedia.org/wiki/MRNA_vaccine#Amplification https://en.wikipedia.org/wiki/MRNA_vaccine#Amplification but not enough for my curiosity level.)